Format

Send to

Choose Destination
See comment in PubMed Commons below
Hosp Med. 1999 Dec;60(12):873-7.

Palivizumab: an overview.

Author information

1
Neonatal Unit, St George's Hospital, London.

Abstract

Respiratory syncytial virus (RSV) affects almost all children in their first 2 years of life and can cause severe or even life-threatening disease in some at-risk infants. Treatment is limited and there is currently no safe or effective vaccine. However, a new monoclonal antibody, palivizumab, reduces RSV hospitalization by 55% in at-risk groups if given prophylactically throughout the RSV season.

PMID:
10707171
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center